Denali Therapeutics Inc. to Post FY2025 Earnings of ($2.65) Per Share, Leerink Partnrs Forecasts (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLI) – Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued on Tuesday, September 3rd. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($2.65) per share for the year, down from their previous estimate of ($2.60). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.54) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ FY2026 earnings at ($2.90) EPS, FY2027 earnings at $0.30 EPS and FY2028 earnings at $0.40 EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09. The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $10.00 million. The business’s revenue for the quarter was down 99.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.30 EPS.

Several other brokerages have also recently commented on DNLI. Bank of America boosted their target price on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Wednesday. Citigroup raised their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Wedbush dropped their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. upped their price target on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.30.

Denali Therapeutics Trading Up 0.4 %

Shares of NASDAQ:DNLI opened at $25.25 on Friday. The company has a 50 day moving average of $23.22 and a 200-day moving average of $20.71. The firm has a market cap of $3.60 billion, a P/E ratio of -26.30 and a beta of 1.40. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $25.90.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the transaction, the director now directly owns 34,404 shares in the company, valued at $761,016.48. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds have recently made changes to their positions in the company. Dana Investment Advisors Inc. raised its stake in Denali Therapeutics by 19.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 34,269 shares of the company’s stock valued at $796,000 after purchasing an additional 5,513 shares during the period. Creative Planning grew its holdings in shares of Denali Therapeutics by 8.7% during the second quarter. Creative Planning now owns 43,033 shares of the company’s stock valued at $999,000 after buying an additional 3,458 shares in the last quarter. Susquehanna Fundamental Investments LLC raised its position in Denali Therapeutics by 5.6% during the second quarter. Susquehanna Fundamental Investments LLC now owns 222,917 shares of the company’s stock valued at $5,176,000 after buying an additional 11,900 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Denali Therapeutics by 15.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 172,281 shares of the company’s stock worth $4,000,000 after acquiring an additional 23,165 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Denali Therapeutics by 58.7% during the 2nd quarter. Millennium Management LLC now owns 619,929 shares of the company’s stock worth $14,395,000 after acquiring an additional 229,313 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.